Feedback / Questions
IM-101 - Immunabs
https://www.businesswire.com/news/home/20250602209751/en/ImmunAbs-Announces-FDA-Phase-2-IND-Approval-of-IM-101-a-Novel-Complement-C5-Inhibitor-for-Treatment-of-Myasthenia-Gravis
Jun 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next